Collaboration - the key to helping patients get better. Jane Griffiths, Company Group Chairman, Janssen




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Collaboration - the key to helping patients get better. Jane Griffiths, Company Group Chairman, Janssen
Released on: June 30, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    One of the biggest challenges for the Pharma industry is getting closer to patients.
  • Summary
  • Transcript
  • Participants
  • Company
One of the biggest challenges for the Pharma industry is getting closer to patients. In an industry that does a huge amount of good in terms of researching developing and commercialising new medicines where they face a need to make sure that access is created for patients but also to make sure that patients are using their medicines to the best extent. Jane Griffiths, Company Group Chairman, Janssen explains to Fintan Walton how Janssen are collaborating with patient organisations, clinicians, patients and other stakeholders to ensure they are all working to the good of the patients and delivering better value.
One of the biggest challenges for the Pharma industry is getting closer to patients. In an industry that does a huge amount of good in terms of researching developing and commercialising new medicines where they face a need to make sure that access is created for patients but also to make sure that patients are using their medicines to the best extent. Jane Griffiths, Company Group Chairman, Janssen explains to Fintan Walton how Janssen are collaborating with patient organisations, clinicians, patients and other stakeholders to ensure they are all working to the good of the patients and delivering better value.
Jane Griffiths
Janssen
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health. Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market – from patients to practitioners, from clinics to hospitals. Headquartered in Titusville, New Jersey, Janssen is named after Dr. Paul Janssen, a leading Belgian researcher, pharmacologist, and general practitioner. Dr. Janssen led a group of researchers to discover a medicine that helped change the way mental health patients were treated. His company, Janssen Pharmaceutica, joined the Johnson & Johnson family of companies in 1961. Our company remains guided by Dr. Janssen’s values of excellence and innovation.